The world’s largest drugmaker is betting big on preventive medicines—and learning from big tech
Catch up on global daily news
Compelling long reads
Tune into captivating conversations
Watch engaging short films
Behind the scenes at The Economist
Our podcast on markets, the economy and business. This week, an interview with David Ricks, CEO of Eli Lilly
It will transform how medicines are made—and the industry itself
Eli Lilly made 11 biotech acquisitions in H1 2026, dominating the industry's M&A total while targeting vaccines, CAR-T, ADCs &…
Patients benefit from faster, cheaper treatments, wherever they are invented
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
It has pulled off yet another striking turnaround
